ReviewClinical reviews in allergy & immunology2013
Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: from bread baking to autoimmunity.
Review in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Meta-analysis of anti-BMJ open · 2020Pooled it
- Early gut mycobiota and mother-offspring transfer.Microbiome · 2017Trial
- Comparative analysis of population with positive anti-gliadin antibody and anti-Saccharomyces cerevisiae antibody.Pakistan journal of medical sciences · 2026Article
- Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.The Journal of pharmacology and experimental therapeutics · 2025Review
- Genetically EncodedACS synthetic biology · 2025Article
- Characterization of Gut Microbiota in Patients with Active Spreading Vitiligo Based on Whole-Genome Shotgun Sequencing.International journal of molecular sciences · 2025Article
- Application of selected lactic acid bacteria isolates for bread production without baker's yeast.Food science and biotechnology · 2024Article
- Global research trends and hotspots on human intestinal fungi and health: a bibliometric visualization study.Frontiers in cellular and infection microbiology · 2024Article
- Antibodies as Models and Tools to DecipherJournal of fungi (Basel, Switzerland) · 2023Review
- ASCA-related antibodies in the blood sera of healthy donors and patients with colorectal cancer: characterization with oligosaccharides related toFrontiers in molecular biosciences · 2023Article
- Characterization of TwoFoods (Basel, Switzerland) · 2022Article
- A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Pharmaceutically Active Microbial AhR Agonists as Innovative Biodrugs in Inflammation.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Probiotic-Induced Tolerogenic Dendritic Cells: A Novel Therapy for Inflammatory Bowel Disease?International journal of molecular sciences · 2021Review
- Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.Nature medicine · 2021Article
- Systemic anti-commensal response to fungi analyzed by flow cytometry is related to gut mycobiome ecology.Microbiome · 2020Article
- Health Impact and Therapeutic Manipulation of the Gut Microbiome.High-throughput · 2020Review
- IgA is the predominant isotype of anti-β2 glycoprotein I antibodies in rheumatoid arthritis.Journal of clinical laboratory analysis · 2020Article
- Yeast-Free Doughs byMicroorganisms · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Saccharomyces cerevisiae is best known as the baker's and brewer's yeast, but its residual traces are also frequent excipients in some vaccines. Although anti-S. cerevisiae autoantibodies (ASCAs) are considered specific for Crohn's disease, a growing number of studies have detected high levels of ASCAs in patients affected with autoimmune diseases as compared with healthy controls, including antiphospholipid syndrome, systemic lupus erythematosus, type 1 diabetes mellitus, and rheumatoid arthritis. Commensal microorganisms such as Saccharomyces are required for nutrition, proper development of Peyer's aggregated lymphoid tissue, and tissue healing. However, even the commensal nonclassically pathogenic microbiota can trigger autoimmunity when fine regulation of immune tolerance does not work properly. For our purposes, the protein database of the National Center for Biotechnology Information (NCBI) was consulted, comparing Saccharomyces mannan to several molecules with a pathogenetic role in autoimmune diseases. Thanks to the NCBI bioinformation technology tool, several overlaps in molecular structures (50-100 %) were identified when yeast mannan, and the most common autoantigens were compared. The autoantigen U2 snRNP B″ was found to conserve a superfamily protein domain that shares 83 % of the S. cerevisiae mannan sequence. Furthermore, ASCAs may be present years before the diagnosis of some associated autoimmune diseases as they were retrospectively found in the preserved blood samples of soldiers who became affected by Crohn's disease years later. Our results strongly suggest that ASCAs' role in clinical practice should be better addressed in order to evaluate their predictive or prognostic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.